Upharmacia June 2017
field audits. 9 applications form
Indian producers are now under
consideration by the Service.
In 2016, the market-share of
foreign drug producers in
values in Ukraine decreased
from 59.2% in 2015 to 57.4%.
In volumes, the market share
improved from 23.2% to 23.7%.
REGULATORY UPDATES
T he N ational L ist of E ssential
M edicines E nactment W ill B e
P ostponed U ntil S ep 1, 2017
On June 29, 2017 the draft
resolution of Cabinet of
Ministers of Ukraine, which
proposes to amend the Cabinet
of Ministers Resolution of
25.03.2009. #333 "Certain
issues of state regulation
of prices for medicines and
medical products” was posted
on the website of the Ministry
of Health of Ukraine for public
discussion. The document
proposes to postpone the date
from which health institutions
funded from state and local
budgets should begin to carry
out government purchases of
medicines registered in Ukraine
and included in the National
List of Essential Medicines until
September 1, 2017.
In addition, the draft decree of
Cabinet of Ministers of Ukraine
provides for postponing the
enactment of the provision on
the obligation of customers
to pre-satisfy in full the
requirements for medicines
www.upharma-c.com
registered in Ukraine and
included in the National List
of Essential Medicines until
January 1, 2018.
In this regard, let us remind you
that according to decree of the
Cabinet of Ministers of March
16, 2017, No. 180, the Cabinet
of Ministers decree No. 1071 of
05.09.1996, which approved the
list of medicines of domestic
and foreign production that can
be purchased by agencies and
health care institutions, fully or
partially funded from the state
and local budgets, expires on
July 1, 2017.
C hanges to D etermination of
I nsulin C ost R eimbursement
A mount
On June 24, 2017, the
amendments made to the
terms of insulin preparations
cost reimbursement approved
by the Cabinet of Ministers of
05.03.2014 No. 73 and 23.03.2016
No. 239 entered into force.
In particular, we are talking
about the official publication
of Resolution of Cabinet of
Provided by
Ministers No. 439 of June 21,
2017.
First of all, the approach to
determining the amount
of insulin preparations
reimbursement at the expense
of the local budget has been
changed. So, henceforth, the
compensation amount for the
cost of drugs may differ from
the reference price set by the
Ministry of Health. The only
condition is the established
upper limit: the amount of such
compensation can not exceed
the reference price.
Also, after making
amendments, special conditions
for reimbursement have
been established for certain
categories of patients, namely:
• adults who are diagnosed
with diabetes at the age of
18 and who are prescribed a
human insulin preparation
in a vial and, if they wish, are
ready to fund the cost of the
human insulin drug in the
7